ultrasound
(4)
Josh DeFonzo Is Shrinking the Surgical Robot
After two decades bringing medical technology to market, the Mendaera co-founder is betting that the next useful robot will fit in a clinician’s hand - and do one ordinary, difficult job well.
Meredith Perry
Meredith Perry is the co-founder and CEO of Elemind, a neurotech company building a wearable headband that reads your brainwaves in real time and nudges them with bursts of sound, marketed as sleep on demand. Before Elemind she was the inventor behind uBeam, the ultrasonic wireless-charging venture she dreamed up as a University of Pennsylvania undergrad and grew into a roughly $40 million, much-debated startup backed by Founders Fund, Andreessen Horowitz, Mark Cuban and Marissa Mayer. A trained paleobiologist and astrobiologist who once did research with NASA, Perry holds dozens of patents and now wants to build what she calls an app store for the brain.
Brad Kreger
Brad Kreger is a medical device and manufacturing executive who became CEO of Baltimore-based CoapTech in November 2025, taking over from co-founder Howard Carolan. He brings nearly three decades of operations experience, most recently turning around metal 3D-printing company Velo3D as its CEO, with earlier senior roles at Fluidigm/Standard BioTools, Thermo Fisher Scientific, and Affymetrix. At CoapTech he leads commercialization of the percutaneous ultrasound gastrostomy (PUG) system, an ultrasound-guided method of placing feeding tubes at the bedside that has been used in more than 1,000 patients.
John McCutcheon
John McCutcheon is President, CEO, and Director of EBR Systems, Inc., the Sunnyvale-based medical device company behind the WiSE CRT system - the world's first FDA-approved leadless solution for left ventricular pacing. With over 40 years in medical device sales, marketing, and general management, McCutcheon has shepherded EBR through pivotal clinical trials, FDA Breakthrough Device Designation, and the landmark FDA approval in April 2025. Before EBR, he led Ceterix Orthopaedics to a $105 million acquisition by Smith & Nephew. He brings a track record of building and selling medical device companies, now steering EBR's commercial launch of a technology that could transform how heart failure patients receive cardiac resynchronization therapy.